Navigation Links
Cell Biosciences Closes $10 Million Series C Financing
Date:4/9/2009

PALO ALTO, Calif., April 9 /PRNewswire/ -- Cell Biosciences, a provider of nanoproteomic analysis systems to life science researchers, today announced the closing of a $10 million Series C financing led by its largest shareholder, the Wellcome Trust. Existing investors Domain Associates, Latterell Venture Partners, Novo A/S, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing.

"We are very happy to announce this financing in the current economic environment and we believe it represents a strong vote of confidence by our investors in the potential of the technology and team at Cell Biosciences," said Tim Harkness, President and Chief Executive Officer of Cell Biosciences. "This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market."

The Cell Biosciences platform is an ultrasensitive nanofluidic immunoassay system designed to analyze proteins in extremely small biological samples. Researchers use our products to discover subtle details about phosphoprotein signaling in a wide variety of biological systems. Cell Biosciences has sold systems and established direct distribution organizations in North America and Europe. This month the company will launch its next generation protein analysis system, the CB1000, at the American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado.

"We continue to believe that the Cell Biosciences platform is an important enabling technology for biomarker discovery and ultimately can make a real difference in patient care," added Julie Eskay-Eagle, Cell Biosciences board member and the Head of Health Care Investments for the Wellcome Trust.

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay pro
'/>"/>

SOURCE Cell Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... 18, 2013 A new look at ... and other trends will highlight technical sessions at ... fall. In its 33rd year, the three-day event is ... of key suppliers, approximately 100 technical presentations and numerous ... international society for optics and photonics , the meeting ...
(Date:6/19/2013)... Adding to their already extensive supply ... Simport’s Dropette® and Heathrow Scientific disposable plastic ... basic biology, chemistry and any type of liquid handling ... 35 years, Simport has been supplying the science community ... the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... RUTHERFORD, N.J. , Feb. 10 Cambrex Corporation (NYSE: ... December 31, 2009 . , Highlights , ... sales decreased 15.8% compared to fourth quarter 2008.  For the full year ... foreign currency. EBITDA was $9.4 million in the fourth ...
... , , ... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer,of alternative drug ... , Ph.D., was chosen to lecture at the Third,International Conference on ... Basel, Switzerland on February 11, 2010 . Dr. Kidron,will ...
... , PLANTATION, Fla. and ... Biotechnology Inc., a full service Contract Biomanufacturing Company ... agents, jointly announced today their collaborative agreement on ... customer projects in Nuclear Medicine involving Chelation, Bioconjugation ...
Cached Biology Technology:Cambrex Reports Fourth Quarter and Full Year 2009 Results 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 3Cambrex Reports Fourth Quarter and Full Year 2009 Results 4Cambrex Reports Fourth Quarter and Full Year 2009 Results 5Cambrex Reports Fourth Quarter and Full Year 2009 Results 6Cambrex Reports Fourth Quarter and Full Year 2009 Results 7Cambrex Reports Fourth Quarter and Full Year 2009 Results 8Cambrex Reports Fourth Quarter and Full Year 2009 Results 9Cambrex Reports Fourth Quarter and Full Year 2009 Results 10Cambrex Reports Fourth Quarter and Full Year 2009 Results 11Cambrex Reports Fourth Quarter and Full Year 2009 Results 12Cambrex Reports Fourth Quarter and Full Year 2009 Results 13Cambrex Reports Fourth Quarter and Full Year 2009 Results 14Cambrex Reports Fourth Quarter and Full Year 2009 Results 15Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 2Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:6/19/2013)... of Pittsburgh has developed antibacterial compounds, derived from ... potential treatments for drug-resistant bacterial infections and appear ... quite small, making them inexpensive and easy to ... 2013 issue of the journal Antimicrobial Agents ... probable applications will likely be the chronic bacterial ...
(Date:6/19/2013)... , June 19, 2013 MedNet ... in clinical study management systems, is pleased to announce ... be held June 23-27 in Boston ... MedNet, a recognized leader in cloud-based eClinical solutions, has ... will be showcasing iMedNet™ EDC , ...
(Date:6/19/2013)... is the most potent physiological anabolic agent for ... synthesis of lipids, protein and carbohydrates, and inhibiting ... It also plays a major role in stimulating ... is metabolized and removed from the blood following ... molecular mechanisms by which insulin regulates glucose uptake ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2
... and likely to die of - heart disease compared ... are to blame, according to a new University of Leicester ... Maciej Tomaszewski, New Blood Lecturer in Cardiovascular Medicine in the ... that this "male disadvantage" may be related to the sex-specific ...
... an agreement was reached by the Alliance for a ... sales restrictions on "competitive foods" such as soft drinks ... say limiting the availability of soft drinks at school ... elementary school children. In a study of more ...
... Tech have used skin cells to create artificial bones ... into other tissues such as tendons or ligaments. The ... softer tissue rather than the sudden shift of previously ... and allowing them to handle weight more successfully. The ...
Cached Biology News:Sex hormones link to heart risk 2Engineers create bone that blends into tendons 2
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
Biology Products: